128 related articles for article (PubMed ID: 37328115)
1. Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome.
Olaniyi KS; Areloegbe SE; Areola ED; Sabinari IW; Fafure AA; Agbana RD; Atuma CL; Shah MZUH; Ajadi IO; Olatunji LA
Toxicol Appl Pharmacol; 2023 Aug; 473():116604. PubMed ID: 37328115
[TBL] [Abstract][Full Text] [Related]
2. Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS.
Olaniyi KS; Oniyide AA; Adeyanju OA; Ojulari LS; Omoaghe AO; Olaiya OE
Toxicol Appl Pharmacol; 2021 Jan; 411():115381. PubMed ID: 33359182
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone reversed hepato-ovarian triglyceride accumulation caused by letrozole-induced polycystic ovarian syndrome: tissue uric acid-a familiar foe.
Adeyanju OA; Falodun TO; Michael OS; Soetan OA; Oyewole AL; Agbana RD
Naunyn Schmiedebergs Arch Pharmacol; 2020 Jun; 393(6):1055-1066. PubMed ID: 31925474
[TBL] [Abstract][Full Text] [Related]
4. Suppression of PCSK9/NF-kB-dependent pathways by acetate ameliorates cardiac inflammation in a rat model of polycystic ovarian syndrome.
Olaniyi KS; Areloegbe SE
Life Sci; 2022 Jul; 300():120560. PubMed ID: 35452635
[TBL] [Abstract][Full Text] [Related]
5. Role of PCSK9 in lipid metabolic disorders and ovarian dysfunction in polycystic ovary syndrome.
Wang M; Zhao D; Xu L; Guo W; Nie L; Lei Y; Long Y; Liu M; Wang Y; Zhang X; Zhang L; Li H; Zhang J; Yuan D; Yue L
Metabolism; 2019 May; 94():47-58. PubMed ID: 30768966
[TBL] [Abstract][Full Text] [Related]
6. Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model.
Areloegbe SE; Peter MU; Oyeleke MB; Olaniyi KS
BMC Endocr Disord; 2022 Sep; 22(1):224. PubMed ID: 36071485
[TBL] [Abstract][Full Text] [Related]
7. Very low dose spironolactone protects experimentally-induced polycystic ovarian syndrome from insulin-resistant metabolic disturbances by suppressing elevated circulating testosterone.
Adeyanju OA; Falodun TO; Fabunmi OA; Olatunji LA; Soladoye AO
Chem Biol Interact; 2019 Sep; 310():108742. PubMed ID: 31295448
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of PCSK9 levels and its genetic polymorphisms in women with polycystic ovary syndrome.
Xavier LB; Sóter MO; Sales MF; Oliveira DK; Reis HJ; Candido AL; Reis FM; Silva IO; Gomes KB; Ferreira CN
Gene; 2018 Feb; 644():129-136. PubMed ID: 29109005
[TBL] [Abstract][Full Text] [Related]
9. Agaricus Subrufescens ameliorates ovarian dysfunction and regulates altered biochemical parameters in rats with Letrozole induced polycystic ovarian syndrome.
Bukke SPN; Pathange BBR; Karumanchi SK; Marri J; Boyina R; Rachamsetty K; Manchikalapati B; Odoma S; Hussaini B
J Ovarian Res; 2023 Nov; 16(1):221. PubMed ID: 37993900
[TBL] [Abstract][Full Text] [Related]
10. Low-dose spironolactone abates cardio-renal disorder by reduction of BAX/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model.
Peter MU; Areloegbe SE; Akintayo CO; Oniyide AA; Aturamu A; Olaniyi KS
Can J Physiol Pharmacol; 2022 Sep; 100(9):890-902. PubMed ID: 35771488
[TBL] [Abstract][Full Text] [Related]
11. Alleviation of adipose-hepatic glycolipid dysregulation by acetate in experimental PCOS model is associated with NF-κB/NLRP3 repression.
Olaniyi K; Areloegbe S
Can J Physiol Pharmacol; 2023 Dec; 101(12):630-641. PubMed ID: 37590975
[TBL] [Abstract][Full Text] [Related]
12. Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation.
Xiao HB; Sun ZL; Zhang HB; Zhang DS
Pharmacol Rep; 2012; 64(4):889-95. PubMed ID: 23087140
[TBL] [Abstract][Full Text] [Related]
13. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
14. High-salt diet induces dyslipidemia through the SREBP2/PCSK9 pathway in dahl salt-sensitive rats.
Ou-Yang YN; Deng FF; Wang YJ; Chen M; Yang PF; Yang Z; Tian Z
Biochimie; 2024 Jan; 216():34-45. PubMed ID: 37844755
[TBL] [Abstract][Full Text] [Related]
15. Acetate restores hypothalamic-adipose kisspeptin status in a rat model of PCOS by suppression of NLRP3 immunoreactivity.
Olaniyi KS; Areloegbe SE; Oyeleke MB
Endocrine; 2022 Dec; 78(3):628-640. PubMed ID: 36114434
[TBL] [Abstract][Full Text] [Related]
16. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
Shrestha P; van de Sluis B; Dullaart RPF; van den Born J
Cell Signal; 2019 Mar; 55():53-64. PubMed ID: 30550765
[TBL] [Abstract][Full Text] [Related]
17. The role of proprotein convertase subtilisin/kexin type-9 concentration and paraoxonase 1 activities in the blood of women with polycystic ovary syndrome.
Bizoń A; Franik G; Madej P
Environ Toxicol Pharmacol; 2021 May; 84():103612. PubMed ID: 33571670
[TBL] [Abstract][Full Text] [Related]
18. Hyperhomocysteinemia and hyperandrogenemia share PCSK9-LDLR pathway to disrupt lipid homeostasis in PCOS.
Mondal K; Chakraborty P; Kabir SN
Biochem Biophys Res Commun; 2018 Sep; 503(1):8-13. PubMed ID: 29660344
[TBL] [Abstract][Full Text] [Related]
19. Acetate circumvents impaired metabolic switch in skeletal muscle of letrozole-induced PCOS rat model by suppression of PDK4/NLRP3.
Olaniyi KS; Areloegbe SE
Nutrition; 2023 Mar; 107():111914. PubMed ID: 36521396
[TBL] [Abstract][Full Text] [Related]
20. Diacerein ameliorates letrozole-induced polycystic ovarian syndrome in rats.
Ibrahim YF; Alorabi M; Abdelzaher WY; Toni ND; Thabet K; Hegazy A; Bahaa HA; Batiha GE; Welson NN; Morsy MA; Venugopala KN; Abdel-Aziz AM
Biomed Pharmacother; 2022 May; 149():112870. PubMed ID: 35367769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
